An interventional study of exosomes injection and Topical Minoxidil 5% in Androgenetic Alopecia and Exosomes, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Tanta University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.
Among the 31 studies testing minoxidil in Alopecia, this one is the 21st largest by enrollment, is one of 5 that started in 2023, is one of 8 with no phase, and was the 31st registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:
Kasr El Aini Hospital · Sites in Egypt
Ages 18–50 · Men only · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18–40 · Women only
Sohag University · Sites in Egypt
Ages 15–60 · Women only · Healthy volunteers
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+ · Women only
Eurofarma Laboratorios S.A. · Sites in Brazil
Ages 18–60 · Men only
By country, each count listing its studies:
Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 8 · Phase 4 3
First in 2003; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 60 across the 31 interventional studies. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 31 have an industry lead sponsor. The 10 most frequent:
Tanta University is the lead sponsor of 1,013 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Tanta University has 2 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
1 of the studies testing minoxidil in Alopecia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05778825Memorial Sloan Kettering Cancer CenterA Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing minoxidil in Alopecia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Androgenetic alopecia (AGA) is a common form of hair loss characterized by progressive hair follicle miniaturization. This prospective randomized comparative study evaluates the efficacy and safety of intradermal exosome injections compared with 5% topical minoxidil in patients with AGA. Forty patients were randomly assigned to receive either intradermal exosome injections or topical minoxidil for three months, with clinical, trichoscopic, patient-reported, and safety outcomes assessed at baseline, after treatment, and at 3-month follow-up.
Androgenetic alopecia is the most common form of hair loss and is associated with progressive shortening of the anagen phase and miniaturization of hair follicles. Conventional treatments such as topical minoxidil have variable efficacy and require continued use to maintain results. Exosome-based therapy has emerged as a potential regenerative approach because exosomes can deliver bioactive molecules that may stimulate hair follicle activity and promote the anagen phase.
This prospective, randomized, comparative study included 40 patients with confirmed androgenetic alopecia recruited from the Dermatology and Venerology Department outpatient clinic at Tanta University Hospitals. Participants were randomly allocated using a computer-generated sequence into two equal groups of 20 patients each. Group A received intradermal injections of adipose-derived mesenchymal stem cell exosomes every four weeks for three months, while Group B applied 5% topical minoxidil twice daily for three months.
Treatment efficacy was evaluated using clinical assessment, standardized scalp photography, the Global Aesthetic Improvement Scale (GAIS), trichoscopic assessment of hair density and shaft diameter, and histopathological/immunohistochemical evaluation in biopsied patients. Patient satisfaction and adverse events were also recorded. Assessments were performed at baseline, immediately after the 3-month treatment period, and after a further 3-month follow-up period.
The study aims to provide comparative clinical evidence regarding the efficacy and safety of intradermal exosome therapy versus topical minoxidil for androgenetic alopecia. The protocol received approval from the Institutional Review Board of Tanta University (Approval Code: 36264MS541/3/24), and written informed consent was obtained from all participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Had not received any treatment for AGA for at least 6 months before study initiation.
Provided written . Agreed to attend the scheduled follow-up assessments and undergo photographic documentation.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intradermal injections of 1 mL of Exomide
Other: exosomes injection
5% topical minoxidil solution
Drug: Topical Minoxidil 5%
intradermal injections of 1 mL of Exomide
5% topical minoxidil solution
Global Aesthetic Improvement Scale (GAIS) score
Clinical improvement was assessed by three blinded dermatologists using the GAIS, categorized as Poor (0-25%), Moderate (26-50%), Marked (51-75%), or Excellent (76-100%).
Time frame: Baseline, immediately after treatment (3 months), and 3-month follow-up.
Ran from Apr 2023 to primary completion in May 2024, 13 months.
Of 85 non-industry interventional studies with no phase under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's 13 months is close to that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Minoxidil